Little is known about clinical features and survival outcome in locally advanced unresectable extrahepatic cholangiocarcinoma (EHC). The aim was to investigate the clinical features and the survival outcome in these patients, and to evaluate the role of palliative resections in locally advanced unresectable EHC. Methods: Between 1995 and 2007, 280 patients with locally advanced unresectable EHC were identified. Clinical, pathologic, and survival data were investigated. A comparative analysis was done between those who received palliative resection (PR) and those who were not operated on (NR). Results: The overall median survival of the study population was 10±1 months, and the 3-and 5-year survival rates (YSR) were 8.5% and 2.5%, respectively. The median survival, 3-and 5-YSR of PR were 23 months, 32.1% and 13.1%, respectively. For NR, they were 9 months, 3.9% and 0%, which were significantly worse than PR (p＜0.001). In univariate analysis, T classification, N classification, tumor location, palliative resection, adjuvant treatment, chemotherapy, and radiation therapy were factors that showed survival difference between PR and NR. Regional lymph node metastasis (RR, 2.084; 95% CI, 1.491-2.914; p＜0.001), non-resections (RR, 2.270; 95% CI, 1. 497-3.443; p＜0.001), and no chemotherapy (RR, 1.604; 95% CI, 1.095-2.349; p=0.015) were identified as risk factors for poor outcome on multivariate analysis. Conclusions: Without evidence of systemic disease, palliative resection may provide some survival benefit in selected locally advanced unresectable EHCs and adjuvant treatment may further improve survival outcome. (Korean J Hepatobiliary Pancreat Surg 2014;18:1-8)
INTRODUCTION
Cholangiocarcinoma can occur anywhere along the biliary tree. Cholangiocarcinoma can be broadly divided into intrahepatic and extrahepatic cholangiocarcinoma. Extrahepatic cholangiocarcinoma can further be divided into perihilar cholangiocarcinoma and distal bile duct cancer. 1 Perihilar cholangiocarcinoma and distal bile duct cancer comprise extrahepatic cholangiocarcinoma (EHC). EHCs are rare malignant tumors in western countries, but they are relatively frequent tumors in some Asian countries. 2, 3 Surgical resection with negative resection margin is the only effective treatment for long-term survival. The 5-year survival rate is reported to range from 30% to 45% after R0 resection, and 14% to 30% after R1 resection. [4] [5] [6] Recent advancements of imaging modalities and operative techniques have improved the resection rate of EHCs. [6] [7] [8] Yet, less than 30% of EHC patients are known to qualify for formal curative resection and those who are unresectable will receive biliary drainage. 9, 10 In addition, even among those who undergo resection with curative intent, only R2 resection will be possible due to severely advanced state. However, not much is known about unresectable EHCs and the benefit of R2 resections in these patients.
The purpose of this study was to investigate the clinical features and the survival outcome of locally advanced un- 
RESULTS

Overall demographics
The mean age of the study population was 66.0±11.3 years, and male dominance was observed (65% therapy. These demographics are described in Table 1 .
Pathologically, there were 5 patients (1.8%) of T1, 29 
Clinicopathologic comparison of PR and NR groups
The mean ages (65.5 vs. 66.1 years, p=0.751) and the gender ratios (1.6 : 1 vs. 1.9 : 1, p=0.625) were not different between NR and PR groups. The tumor location did not differ (83.8% perihilar in NR vs. 84.6% perihilar in PR, p=0.900). The initial CEA (3.5 vs. 4.7 ng/ml, p=0.414), initial CA-19-9 (1,959.1 vs. 2,345.6 U/ml, p=0.719), and highest bilirubin levels (10.9 vs. 12.9 mg/dl, p=0.228) did not reveal any statistical difference between the groups. The biliary drainage method did not differ between NR and PR groups (p=0.385). Although N classification seemed to differ statistically (p=0.001), when comparing N0 and N1 only, the N classification was not different between the groups (p=0.889). These clinicopathologic features are described in Table 2 .
The proportions that received adjuvant therapy (p＜0.001) were significantly different. In terms of adjuvant therapy, only 10.8% of the NR group was confirmed to have received adjuvant therapy whereas 56.4% of the PR group was confirmed. T classification showed a significant difference between the groups. The NR group tended to have higher T classifications (p＜0.001) with 93.0% of T3/T4 tumors, whereas the PR group had 56.4% of T3/T4 tumors.
Comparison of survival outcome between PR and NR groups
The median survival, 3-, and 5-YSR of PR group were 23 months, 32.1%, and 13.1%, respectively. For NR group, they were 9 months, 3.9%, and 0%. The survival outcome of PR was significantly better than that of NR (p＜0.001, Fig. 2 ). Table 3 .
Subgroup analysis of T classification demonstrated that
PR showed better survival outcome compared to NR up to T3 with statistical significance (median survival 21 months for PR vs. 9 months for NR, p＜0.001, Fig. 3A ).
However, in T4 tumors, the benefit of palliative resection was lost (median survival 11 months for PR vs. 9 months for NR, p=0.330, Fig. 3B ).
In terms of adjuvant treatment, 49 patients were con- Adjuvant radiotherapy is usually reported to have limited survival benefit in EHCs, 22 but there are increasing reports of a potential benefit, especially in positive margin patients. [23] [24] [25] [26] [27] Yet, the benefit of radiotherapy in locally advanced unresectable tumor needs to be further elucidated.
According to the current results, although adjuvant treatment seems to provide a survival benefit, adjuvant treatment alone is not sufficient. The survival outcome of PR without adjuvant treatment was similar to or better than that of NR with adjuvant treatment. Furthermore, adjuvant treatment without resection only provided a marginal survival benefit.
Based on our findings, an algorithm may be proposed 
